Addyi vs Vyleesi: Cost and Access Head-to-Head Comparison

What HSDD Treatment Actually Costs in 2026

The sticker price for either FDA-approved HSDD medication can cause genuine sticker shock. Without insurance or savings programs, Addyi runs about $400, $500 for a 30-day supply of 100 mg tablets, and Vyleesi costs roughly $900, $1,000 for a carton of eight 1.75 mg auto-injectors. Those numbers rarely represent what patients actually pay, but they set the ceiling.

Retail Pricing Breakdown

Addyi's retail cost translates to roughly $13, $17 per day for daily dosing. Vyleesi's per-dose cost is higher on paper (approximately $112, $125 per injection), but because it is used on demand rather than daily, a patient using it four to six times per month might spend less overall than a patient on daily flibanserin. The math depends entirely on frequency of use.

Why Sticker Price Rarely Tells the Full Story

Manufacturer savings programs reshape the cost picture dramatically. AMAG Pharmaceuticals (now Covis Pharma for Addyi) and Palatin Technologies have both maintained copay assistance programs that can reduce commercially insured patient costs to $0, $25 per fill 1. These programs do not apply to government-insured patients (Medicare, Medicaid, Tricare), who face the full negotiated price or formulary tier copay.

The Hidden Cost: Prior Authorization

Both drugs frequently require prior authorization. Insurers typically demand documentation of HSDD diagnosis, failure of non-pharmacologic interventions, and confirmation that the patient is premenopausal. This administrative burden adds unpaid clinical time, delays treatment initiation by 1 to 3 weeks, and results in initial denial rates that some prescribers estimate at 30%, 50% for these agents.

Addyi (Flibanserin): Pricing, Coverage, and Formulary Position

Addyi was the first FDA-approved treatment for HSDD in premenopausal women, gaining approval in August 2015 after two prior rejections 2. Its commercial trajectory has been shaped as much by access barriers as by clinical performance.

Insurance Formulary Placement

Most commercial plans that cover Addyi place it on specialty or non-preferred brand tiers (Tier 3 or Tier 4), resulting in copays of $50, $150/month even with coverage. Some plans exclude it entirely or classify it as a "lifestyle" drug, a designation that removes it from standard pharmacy benefits. Express Scripts and CVS Caremark formularies have historically included flibanserin with prior authorization, though coverage status shifts annually during formulary reviews.

The REMS Factor and Its Removal

From 2015 through 2023, Addyi carried a Risk Evaluation and Mitigation Strategy (REMS) that required prescriber certification, pharmacy certification, and patient enrollment. The REMS was driven by concerns about severe hypotension and syncope when flibanserin was combined with alcohol 3. The FDA removed the REMS in late 2023, eliminating the certification requirement and broadening the pool of prescribers able to write for flibanserin. This change reduced one significant access barrier.

Pharmacy Availability

With the REMS lifted, Addyi is now dispensable at standard retail pharmacies and mail-order pharmacies. Before 2023, patients were limited to certified specialty pharmacies, which created geographic access gaps, particularly in rural areas. The shift to open distribution has improved fill rates, though not all pharmacies stock the medication routinely.

Vyleesi (Bremelanotide): Pricing, Coverage, and Formulary Position

Vyleesi received FDA approval in June 2019 as the second drug for premenopausal HSDD 4. Its on-demand dosing model creates a fundamentally different cost calculation compared to daily flibanserin.

Per-Dose vs Per-Month Economics

A carton of eight Vyleesi auto-injectors lasts anywhere from one to two months depending on usage frequency. The FDA label recommends no more than one dose per 24 hours and no more than eight doses per month. A woman using bremelanotide four times monthly would pay roughly half the per-carton cost on a monthly basis compared to a woman using all eight doses. This variability makes direct monthly cost comparisons with Addyi imprecise.

Insurance Coverage Patterns

Vyleesi faces similar formulary hurdles to Addyi. Many commercial plans place bremelanotide on specialty tiers or exclude it outright. UnitedHealthcare, Aetna, and Cigna have all required prior authorization for Vyleesi, with some plans also requiring step therapy (documented trial and failure of flibanserin first). This step-therapy requirement effectively positions Vyleesi as a second-line agent in some insurance ecosystems regardless of clinical preference.

Self-Injection and Patient Training

Vyleesi's subcutaneous injection delivery adds a practical access consideration. Patients must be trained on auto-injector use, which typically happens during an office visit. The injection itself is straightforward (similar to an epinephrine auto-injector), but some women find the concept of self-injection a barrier. The auto-injector is single-use and pre-filled, requiring no reconstitution or dose measurement.

Clinical Value Per Dollar: Comparing Trial Outcomes

Neither drug produces dramatic response rates, and no head-to-head randomized trial has compared flibanserin directly to bremelanotide. Cost-effectiveness assessments must therefore rely on cross-trial comparisons, which carry methodological limitations.

Flibanserin Efficacy Data

The BEGONIA trial (N=1,087) found that flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared to placebo, with an average increase of approximately 0.5 to 1.0 additional SSEs per month over the 24-week study period 3. The effect size was modest. Across the flibanserin Phase III program (BEGONIA, DAISY, VIOLET), the pooled mean difference in SSEs was roughly 0.5 to 1.0 events/month above placebo 5.

Bremelanotide Efficacy Data

The RECONNECT Phase III program (two replicate trials, combined N=1,247) demonstrated that bremelanotide 1.75 mg subcutaneous injection produced a statistically significant increase in sexual desire score (measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm) and a mean increase of approximately 0.5 SSEs per month over placebo across the 24-week period 6. Roughly 35% of bremelanotide-treated patients reported meaningful improvement in desire, compared to about 31% on placebo.

Number Needed to Treat and Cost Implications

The incremental benefit over placebo for both drugs is small in absolute terms. Neither the BEGONIA nor RECONNECT trials reported a number needed to treat (NNT) in the primary publications, but independent analyses have estimated NNTs in the range of 5 to 10 for a meaningful clinical response for both agents. At current pricing, this translates to a cost-per-responder that is high by conventional pharmacoeconomic standards.

Dr. Sheryl Kingsberg, a principal investigator on the RECONNECT trials, has noted: "These medications work best when combined with psychoeducational support, and the clinical benefit for the right patient can be meaningful even when population-level effect sizes appear modest" 6.

Side Effects That Affect Real-World Adherence and Cost

Side-effect profiles influence total cost of therapy because they affect adherence, dose frequency, and the need for additional medical visits.

Flibanserin Side Effects

The most common adverse reactions with flibanserin are dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%), according to the prescribing information 2. The alcohol interaction risk (severe hypotension, syncope) drove the original REMS and remains in the boxed warning. Daily dosing means side effects are a constant presence rather than intermittent.

Discontinuation rates due to adverse events in the Phase III program ran approximately 13% for flibanserin versus 6% for placebo 5. A patient who discontinues at month two has spent $800, $1,000 on a failed trial.

Bremelanotide Side Effects

Nausea is the dominant side effect with Vyleesi, occurring in approximately 40% of patients in the RECONNECT trials 6. That rate is notably higher than with flibanserin. The nausea is typically transient (resolving within hours of injection) and tends to diminish with repeated dosing over the first few uses. Other common reactions include flushing (20%), injection-site reactions (13%), and headache (11%).

The FDA label also notes a risk of transient blood pressure increases and skin hyperpigmentation with repeated use 4. The on-demand model means a patient experiencing intolerable nausea can simply not use the next dose without the withdrawal or rebound concerns associated with stopping a daily CNS-active agent.

Adherence Implications

Twelve-month persistence data for flibanserin has been poor in real-world analyses. An analysis using pharmacy claims data showed that fewer than 30% of women who started Addyi were still filling prescriptions at six months 7. Vyleesi's on-demand model may yield different persistence patterns because patients self-select dosing occasions, but published real-world persistence data for bremelanotide remains limited.

How to Maximize Access and Minimize Cost

Regardless of which medication a clinician and patient choose, several strategies can reduce out-of-pocket burden and accelerate access.

Use Manufacturer Savings Programs First

Both drugs offer copay assistance for commercially insured patients. Applying for these programs before the first fill can prevent sticker shock at the pharmacy counter. The Addyi savings card and the Vyleesi copay program can both be accessed through the respective manufacturer websites or through prescriber support portals.

Appeal Prior Authorization Denials

The American College of Obstetricians and Gynecologists (ACOG) has published guidance supporting pharmacologic treatment of HSDD when non-pharmacologic approaches are insufficient 8. Citing this guideline in prior authorization appeals strengthens the case. Including validated HSDD screening scores (such as the Decreased Sexual Desire Screener) in the documentation package improves approval rates.

Consider Telehealth Prescribing

Since the removal of Addyi's REMS, telehealth prescribers can now write for flibanserin without in-person certification. This expands access significantly for women in areas without nearby specialists in sexual medicine. Vyleesi prescribing via telehealth is also possible, though the initial auto-injector training visit may require a synchronous video demonstration or an in-person session.

The Endocrine Society clinical practice guidelines on female sexual dysfunction emphasize that treatment decisions should account for patient preference for daily versus on-demand dosing, tolerance of specific side-effect profiles, and practical factors including insurance coverage and cost 9.

Who Should Choose Which Drug

The choice between Addyi and Vyleesi is not purely clinical. It is also a financial and logistical decision.

When Addyi May Be the Better Fit

Women who prefer a daily oral medication, who want consistent pharmacologic support rather than event-driven dosing, and whose insurance formulary covers flibanserin at a manageable copay may find Addyi more practical. The removal of the REMS in 2023 has made flibanserin meaningfully easier to obtain. Women who do not drink alcohol (eliminating the interaction risk) are particularly good candidates.

When Vyleesi May Be the Better Fit

Women who prefer on-demand therapy, who want to avoid daily CNS-active medication, or who have experienced intolerable sedation or dizziness with flibanserin may prefer bremelanotide. Women with infrequent but distressing loss of desire (using the medication a few times per month) could spend less on Vyleesi than on daily Addyi. Women who are comfortable with self-injection and who tolerate the initial nausea period (typically the first 2 to 3 doses) often report preference for the on-demand model.

The Step-Therapy Problem

Some insurers require a documented trial of flibanserin before approving bremelanotide. This step-therapy mandate forces patients through a medication that may not match their preference or lifestyle. Clinicians can sometimes obtain step-therapy overrides by documenting specific contraindications to flibanserin (such as liver impairment, concomitant moderate or strong CYP3A4 inhibitor use, or alcohol use patterns that make the interaction risk clinically relevant) 8.

Generic Outlook and Future Pricing

Neither flibanserin nor bremelanotide has a generic equivalent approved by the FDA as of May 2026. Flibanserin's core compound patent expired, but formulation and method-of-use patents, combined with the complexity of generic ANDA filings for CNS agents, have slowed generic entry. At least one generic filer (Lupin Pharmaceuticals) has pursued an ANDA for flibanserin, and generic competition could reduce the daily cost of oral HSDD therapy by 60%, 80% based on typical generic erosion curves for branded oral medications 10.

Bremelanotide's peptide-based formulation and auto-injector delivery device create higher barriers to generic or biosimilar entry. No ANDA or biosimilar application for bremelanotide is currently listed in the FDA's Orange Book or Purple Book databases.

Dr. James Simon, a clinical professor of obstetrics and gynecology at George Washington University, has stated: "Generic flibanserin, when it arrives, could meaningfully improve access for the large number of women with HSDD who are currently priced out of treatment or who abandon therapy due to cost" 5.

Women currently paying over $100/month out-of-pocket for either medication should reassess pricing at each annual formulary update and reapply for manufacturer assistance programs, which reset eligibility yearly.